Crossmark

Antibodies against chemokine receptors CXCR3 and CXCR4 predict progressive deterioration of lung function in patients with systemic sclerosis

Crossref DOI link: https://doi.org/10.1186/s13075-018-1545-8

Published Online: 2018-03-22

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Weigold, Florian

Günther, Jeannine

Pfeiffenberger, Moritz

Cabral-Marques, Otavio

Siegert, Elise

Dragun, Duska

Philippe, Aurélie

Regensburger, Ann-Katrin

Recke, Andreas

Yu, Xinhua

Petersen, Frank

Catar, Rusan

Biesen, Robert

Hiepe, Falk

Burmester, Gerd R.

Heidecke, Harald

Riemekasten, Gabriela
Funding

Funding for this research was provided by:

Deutsche Forschungsgemeinschaft (1056-11-1/2)

Mirjam Lichy foundation
License Information

Text and Data Mining valid from 2018-03-22
More Information

Article History

Received: 11 September 2017

Accepted: 18 February 2018

First Online: 22 March 2018

Ethics approval and consent to participate

: Ethical approval and signed consent of the patients were obtained (EA1/042/09, EA1/013/05, EA1/160/10; Ethics committee, Charité University Hospital, Berlin, Germany).

: Not applicable.

: GR is an advisor for CellTrend. HH is manager of CellTrend. The remaining authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.